Extreme hyperbilirubinemia: An indicator of morbidity and mortality in sickle cell disease

Abstract

BACKGROUND Sickle cell disease (SCD) is a disorder that results in increased hospitalizations and higher mortality. Advances in management have resulted in increases in life expectancy and led to increasing awareness of sickle cell hepatopathy (SCH). However, its impact in patients on the natural history and outcomes of SCD is not known. Our study aims to describe the prevalence of extreme hyperbilirubinemia (EH), one form of SCH, its effect on morbidity and mortality, and correlations between sickle cell genotype and SCH type. We hypothesize that EH is associated with higher morbidity and mortality. AIM To investigate the effects of EH on morbidity and mortality among patients with SCD. METHODS This retrospective cohort study was performed using a database of patients with SCD treated at Grady Memorial Hospital between May 2004 and January 2017. Patients with EH (defined as total bilirubin above 13.0 mg/dL) were identified. A control group was identified from the same database with patients with total serum bilirubin ≤ 5.0 mg/dL. Electronic medical records were used to extract demographic information, laboratory values, radiology results, current medications, need for transfusions and mortality data. Two samples T -test, chi-squared test and Fisher’s exact test were then used to compare the parameters between the two groups. RESULTS Out of the database, fifty-seven charts were found of patients with bilirubin > 13 mg/dL. Prevalence of severe SCH as defined by EH was 4.8% (57/1172). There were no demographic differences between patients with and without EH. Significant genotypic differences existed between the two groups, with hemoglobin SS SCD being much higher in the EH group ( P < 0.001). Patients with severe EH had a significant elevations in alanine aminotransferase (157.0 ± 266.2 IU/L vs 19.8 ± 21.3 IU/L, P < 0.001), aspartate aminotransferase (256.5 ± 485.9 U/L vs 28.2 ± 14.7 U/L, P < 0.001) and alkaline phosphatase (218.0 ± 176.2 IU/L vs 85.9 ± 68.4 IU/L, P < 0.001). Patients with EH had significantly higher degree of end organ failure measured with quick Sequential Organ Failure Assessment scores (0.42 ± 0.68 vs 0.01 ± 0.12, P < 0.001), increased need for blood products (63% vs 5%, P < 0.001), and exchange transfusions (10.5% vs 1.3%, P = 0.022). CONCLUSION Among patients with SCD, elevated levels of total bilirubin are rare, but indicative of elevated morbidity, mortality, and need for blood transfusions. Large differences in sickle cell genotype also exist, but the significance of this is unknown. ...

Acute Liver Failure in Sickle Cell Disease: A Perfect Storm

“…Underlying liver disease represents a significant cause of morbidity and mortality in patients with SCD [ 9 , 10 ]. Prediction of sickle cell hepatopathy may represent a potential opportunity for risk reduction.…”

Asymptomatic Hepatic Sequestration with Extreme Hyperbilirubinemia in an Adult Homozygous Sickle Cell Patient

“…It is important that the medical community as a whole and more specifically the gastroenterology and hematology/oncology communities are aware of the importance of imaging in asymptomatic sickle cell patients who present with only mild jaundice to prevent hepatic complications. This may entail routine MRCP on patients that present with jaundice, but at the very least bilirubin levels should be obtained [4,5,7]. To our knowledge, this is the first report that describes this unusual scenario with a favorable outcome.…”

“…This increase in hematocrit is potentially dangerous and requires a watchful eye as hyperviscosity can increase the risk of heart failure, stroke, and even acute coronary syndrome, which would then benefit from phlebotomy [4,5]. It should be noted that a liver percutaneous biopsy is no longer recommended and has shown to lead to life-threatening hemorrhage and death in 28%-36% of cases as seen in United Kingdom patients [6][7][8].…”

Predictors associated with sickle cell nephropathy: a systematic review

“…https://doi.org/10.1371/journal.pmed.1000097 developed with more than 1100 subjects. On the other hand, this study does not present any parameter related to kidney function, which provides the missing information of whether AST is related or not with SN 25 . However, Madu et al correlated AST levels and proteinuria, without statistical significance, which also indicates a poor correlation between this predictor and kidney injury 26 .…”